No Data
Pulling Back 6.0% This Week, Collegium Pharmaceutical's NASDAQ:COLL) Three-year Decline in Earnings May Be Coming Into Investors Focus
Despite Lower Earnings Than Three Years Ago, Collegium Pharmaceutical (NASDAQ:COLL) Investors Are up 46% Since Then
Indivior CFO Steps Down From Board After Discussions With Oaktree Capital
Alkermes, DaVita, Jabil, Ralph Lauren, Among Potential M&A Candidates - BofA
US Manufacturing Index Rises To 43, Highest Since 2020
Express News | COLLEGIUM PHARMACEUTICAL Announced That Health Canada Has Approved Its Drug Jornay-PM For The Treatment Of ADHD In Children
Can Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Improve Its Returns?No Data
